TerminatedPHASE2, PHASE3NCT06121375

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Studying Isolated biliary atresia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Intercept Pharmaceuticals
Principal Investigator
Lynda Szczech, MD
Intercept Pharmaceuticals
Intervention
OCA(drug)
Enrollment
28 enrolled
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (24)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06121375 on ClinicalTrials.gov

Other trials for Isolated biliary atresia

Additional recruiting or active studies for the same condition.

See all trials for Isolated biliary atresia

← Back to all trials